SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,328 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,328 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $17.41, for a total transaction of $57,940.48. Following the sale, the senior vice president owned 251,896 shares in the company, valued at $4,385,509.36. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

SiBone Price Performance

Shares of SIBN traded up $0.24 during midday trading on Wednesday, reaching $18.60. The stock had a trading volume of 472,223 shares, compared to its average volume of 442,797. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The company has a market capitalization of $807.05 million, a P/E ratio of -36.47 and a beta of 0.81. The firm’s 50 day moving average price is $15.40 and its 200-day moving average price is $16.72. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The business had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. SiBone has set its FY 2025 guidance at EPS. On average, analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on SIBN shares. Truist Financial reduced their price objective on shares of SiBone from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald set a $25.00 target price on SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Institutional Trading of SiBone

A number of hedge funds have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd bought a new position in SiBone in the first quarter worth $34,000. State of Alaska Department of Revenue acquired a new position in SiBone in the third quarter valued at about $39,000. State of Wyoming bought a new stake in SiBone during the 2nd quarter worth approximately $55,000. Virtus Advisers LLC bought a new stake in shares of SiBone during the first quarter worth $58,000. Finally, Canada Pension Plan Investment Board acquired a new stake in SiBone in the 2nd quarter valued at about $68,000. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.